Somewhere around month four or five, your clinician suggests moving up a dose tier — say, the tirzepatide-class jump from 5mg to 7.5mg. Clinically it's routine. Financially, depending on your provider's billing architecture, it costs anywhere from zero to a documented near-doubling of your monthly bill. Here's the escalation priced across the market's structures.
Key Takeaways
- The same clinical decision — one dose tier up — prices at $0 on flat plans, +$30–80/month on gentle tiers, and +$170/month at known cliff structures.
- The documented cliff example in our tracker: ~$229/month jumping to $399/month at 7.5mg+ — a 74% increase at one escalation.
- Annualized, the spread between structures at higher doses runs well past $1,500/year.
- Ask one question before starting anywhere: 'Show me the complete dose-price schedule, top tier included.' The answer predicts your year-one total better than the headline price.
The Escalation, Priced Three Ways
| Billing structure | At 5mg | At 7.5mg | The increase | Year at 7.5mg |
|---|---|---|---|---|
| Flat plan ($179/mo) | $179 | $179 | $0 | $2,148 |
| Flat annual-commit ($99/mo) | $99 | $99 | $0 | $1,188 |
| Gentle tiers | $199 | $249 | +$50/mo | $2,988 |
| Cliff structure (documented example) | $229 | $399 | +$170/mo (+74%) | $4,788 |
Read the rightmost column: the identical patient on the identical dose pays between $1,188 and $4,788 for the year depending purely on billing architecture chosen months earlier.
Why Cliffs Exist
Higher doses consume more compounded product, so some price slope is defensible cost pass-through. Cliffs are something else: the low tiers are priced as acquisition bait, and the cliff sits exactly where the standard titration path — which most patients follow — will deliver them. It's not hidden, exactly; it's disclosed where marketing doesn't point. Providers with cliff structures are betting you'll price-shop the starter tier and inertia-pay the rest.
The Wrinkle: Not Everyone Escalates
Fairness requires the reverse case: if you're among the patients who respond fully at lower tiers and never climb, a tiered plan's cheap low tiers beat flat pricing — you'd be subsidizing escalations you never take. The problem is sequencing: you don't know your dose destiny at signup. Which is why the decision rule runs on information, not prediction.
The Decision Rule
- Dose unknown (new patient): flat pricing. You're buying insurance against the exact cliff you can't predict, and the standard titration path makes escalation the likely case.
- Dose known and low (proven responder or maintainer): shop tiers at your tier — and confirm step-downs are as frictionless as step-ups.
- Everyone, everywhere: obtain the full dose-price schedule in writing before the first charge. A provider reluctant to show its top tier has answered your question.
Flat-at-Every-Dose Programs We Track
Sesame
Compare treatment availability, consultation and membership charges, pharmacy fees and refill policies. Eligibility and medication choice are determined by a clinician.
Pricing, medication access, service area and plan terms must be confirmed with the provider. This is not a drug-specific checkout link.
Explore Sesame program ↗Affiliate link: we may earn a commission. This is a different provider from the retired program discussed in older comparisons.
Ivím Health
Compare treatment availability, consultation and membership charges, pharmacy fees and refill policies. Eligibility and medication choice are determined by a clinician.
Pricing, medication access, service area and plan terms must be confirmed with the provider. This is not a drug-specific checkout link.
Explore Ivím Health program ↗Affiliate link: we may earn a commission. This is a different provider from the retired program discussed in older comparisons.
Embody
Injectable semaglutide — $149 first month
Our lead injectable pick: physician-supervised semaglutide with clean flat pricing after the intro month.
Compounded medications are not FDA-approved.
Visit Embody Paid linkVerdict: the dose increase is where GLP-1 pricing stops being a headline number and becomes an architecture. Buy the architecture, not the ad.
Affiliate disclosure: Links marked "Paid link" are affiliate links. We may earn a commission if you sign up through them, at no extra cost to you. This supports our independent research.
Compounded medication notice: Compounded medications are not FDA-approved. The FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed. Brand-name alternatives (Wegovy, Ozempic, Zepbound, Rybelsus) are FDA-approved.
Medical disclaimer: This article is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs. Always consult a licensed healthcare provider about diagnosis, treatment, dosing, and whether these medications are appropriate for you.